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Abstract
Objectives. This study aimed to test the performance of the new ACR and EULAR criteria, that include ANA posi-
tivity as entry criterion, in JSLE.
Methods. Performance of the ACR/EULAR-2019 criteria were compared with Systemic Lupus International
Collaborating Clinics (SLICC-2012), using data from children and young people (CYP) in the UK JSLE Cohort Study
(n¼482), with the ACR-1997 criteria used as reference standard. An unselected cohort of CYP positive for ANA
(n¼129) was used to calculate positive/negative predictive values of the criteria.
Results. At both first and last visits, the number of patients fulfilling the different classification criteria varied signifi-
cantly (P < 0.001). The sensitivity of the SLICC-2012 criteria was higher when compared with that of the ACR/EULAR-
2019 criteria at first and last visits (98% vs 94% for first visit, and 98% vs 96% for last visit; P < 0.001), when all avail-
able CYP were considered. The ACR/EULAR-2019 criteria were more specific when compared with the SLICC-2012 cri-
teria (77% vs 67% for first visit, and 81% vs 71% for last visit; P < 0.001). Significant differences between the classifi-
cation criteria were mainly caused by the variation in ANA positivity across ages. In the unselected cohort of ANA-
positive CYP, the ACR/EULAR-2019 criteria produced the highest false-positive classification (6/129, 5%).
Conclusion. In CYP, the ACR/EULAR-2019 criteria are not superior to those of the SLICC-2012 or ACR-1997 crite-
ria. If classification criteria are designed to include CYP and adult populations, paediatric rheumatologists should be
included in the consensus and evaluation process, as seemingly minor changes can significantly affect outcomes.
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JSLE is a severe, multisystem autoimmune/inflammatory
disease characterized by systemic inflammation, tissue
and organ damage, and the presence of autoantibodies
directed against nuclear auto-antigens [1]. Presentation
and outcomes vary significantly between individuals,
which can complicate diagnosis, generation of evidence
through clinical trials, and treatment of patients [2].
Classification criteria are an important tool for ensur-
ing consistent case definition, particularly in relation to
clinical trials. Widely accepted and used criteria for SLE
were developed by the ACR in 1982 [3], and updated in
1997 (ACR-1997). Those criteria include 11 clinical and
laboratory items, 4 being required for classification as
SLE. Each element is weighted equally and (technically)
patients can be classified as SLE in the absence of im-
munological anomalies [4]. Due to concerns that the
ACR criteria may miss some SLE patients, in particular
those with LN and autoantibody positivity but limited
systemic involvement, the Systemic Lupus International
Collaborating Clinics (SLICC-2012) group established
further criteria, including 11 clinical and 6 immunological
items [5]. Each criterion is weighted equally, and a score
of 4 is required for classification as SLE. Of note,
SLICC-2012 also stipulated that patients with LN and
ANA and/or anti-dsDNA antibody positivity can be
defined as SLE, in the absence of other clinical criteria
[5]. Three studies have examined the performance of the
SLICC-2012 criteria in international JSLE cohorts. All
three studies demonstrated higher sensitivity for the
SLICC-2012 criteria (between 92.9 and 98.7%) as com-
pared with the ACR-1997 criteria (between 76.6 and
85.6%) [6–8]. Only one of these studies included a con-
trol group, and therefore was able to assess the specifi-
city: they demonstrated lower specificity for SLICC-2012
(85.3%) when compared with the ACR-1997 criteria
(93.4%) [8].
Recently, the ACR and the EULAR proposed a new
set of classification criteria for SLE (ACR/EULAR-2019
criteria), validated in large adult SLE cohorts [9]. ANA
positivity is a mandatory entry criterion (an ANA titre of
1:80 on human epithelial type 2 cells or equivalent
positive test result). Thereafter, a weighted scoring sys-
tem requires the patient to score 10 points to be clas-
sified as SLE. Similar to the SLICC-2012 criteria, the
ACR/EULAR-2019 criteria are separated into clinical and
immunological features. Based on data from adult
cohorts, the ACR/EULAR-2019 criteria show better
sensitivity than the ACR-1997 criteria (96% vs 83%) and
comparable sensitivity with the SLICC-2012 criteria
(97%). Specificity is the same for the ACR/EULAR-2019
and ACR-1997 criteria (both 93%) and lower for the
SLICC-2012 criteria (84%) [9].
Data on performance of ACR/EULAR-2019 criteria in
JSLE is limited to two relatively small cohorts that both
suggested limited specificity when compared with ACR-
1997 or SLICC-2012 criteria [10, 11]. These studies did
not include longitudinal assessment of the ACR/EULAR-
2019 criteria.
This study aimed to: (i) test performance of the ACR/
EULAR-2019 classification criteria in the UK JSLE
Cohort Study population longitudinally (first vs last visits)
and in relation to age at diagnosis (pre-/peri-/post-pu-
bertal); (ii) investigate ACR/EULAR-2019 criteria in an
unrelated cohort of ANA-positive individuals; and (iii)
compare the performance of the ACR/EULAR-2019 clas-




The UK JSLE Cohort Study [12], collects longitudinal
clinical data from almost all UK paediatric rheumatology
centres (n¼22) treating children and young people
(CYP; up to 18 years) with JSLE. It primarily recruits
patients who meet 4 ACR classification criteria for SLE
[13]. It also recruits patients with probable lupus (fulfilling
<4 ACR criteria), i.e. an experienced consultant clinician
anticipates that the patient will evolve into JSLE. As
such, not all patients fulfil the ACR-1997 classification
criteria for SLE.
The UK JSLE Cohort Study [13] patients included in
this study fulfilled the following inclusion criteria: (1) had
data collected between July 2016 and January 2019
(that included SLICC-2012 classification criteria col-
lected between these time points), (2) an ACR-1997
score of 2 at inclusion, and (3) aged <18 years at the
time of recruitment. The performance of SLE classifica-
tion criteria was tested both in CYP fulfilling 4 ACR-
1997 classification criteria for SLE, and in CYP with a
strong clinical history to suggest a diagnosis of JSLE
but where <4 ACR-1997 criteria were fulfilled at recruit-
ment to the UK JSLE Cohort Study (representing prob-
able JSLE cases). Throughout the manuscript, where all
UK JSLE Cohort patients are included in the analysis
Rheumatology key messages
. In children, the ACR/EULAR-2019 criteria are not superior to the SLICC-2012 or the ACR-1997 criteria for SLE.
. In ANA-positive children, the ACR/EULAR-2019 criteria can result in false-positive classification.
. Paediatricians should be involved in the development of classification criteria to be applied in children.
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(those fulfilling 4 ACR-1997 classification criteria and
probable cases with <4 ACR-1997 criteria at recruit-
ment), they are described as the ‘full UK JSLE Study
Cohort’.
Self-reported ethnicity information was collected accord-
ing to UK National Census categorizations [14]. Data of
mixed-race patients were grouped with those of the asso-
ciated ethnic minority group; a category of ‘other’ was
available for those not wishing to report ethnicity. The
study has full ethical approval (National Research Ethics
Service North West, Liverpool, UK, reference 06/Q1502/
77). Research was carried out in accordance with the
Declaration of Helsinki, and all patients or their legal
guardians gave written confirmed consent.
Data collected
Demographic and clinical data were collected at the
patients’ first clinical assessment at the time of recruitment
to the UK JSLE Cohort Study and at their last study visit,
which is the final or most recent clinical assessment. The
UK JSLE Cohort Study collects the paediatric adaptation
of the 2004 BILAG index (pBILAG-2004) DAS at each clin-
ical encounter [12]. It also collects the ACR-1997 classifi-
cation criteria for SLE at baseline and annually.
Disaggregated pBILAG scores and ACR-1997 classifica-
tion criteria data were used to calculate the ACR/EULAR-
2019 scores (first and last study visits). ANA positivity was
defined as a titre of 1:80. Renal biopsy data were also
obtained where available.
ANA-positive patients presenting over a 12-month
period (i.e. unselected ANA-positive control Cohort)
Clinical and laboratory data were collected from elec-
tronic patient charts of 129 CYP who, as part of an in-
vestigative work-up, were found to be ANA positive (titre
of 1:80, between 01/2018–01/2019) and therefore ful-
filled the ACR/EULAR-2019 entry criterion for SLE. Data
were used to calculate ACR-1997, SLICC-2012 and
ACR/EULAR-2019 scores. The electronic records of
these patients were re-checked 18 months after the ini-
tial positive ANA measurement, to check whether the
patients’ diagnosis had changed over time.
Statistical analysis
Data from the UK JSLE Cohort Study were used to assess
the performance of the ACR/EULAR-2019 classification
criteria for SLE, primarily against the ACR-1997 criteria
(the reference criteria), but also against the SLICC-2012
criteria. Data are primarily expressed descriptively (median,
range, percentages and interquartile ranges). The differen-
ces between age groups, classification criteria and demo-
graphic details were compared using v2 tests. Where
comparisons were made between three different groups
(e.g. age groups) and a significant difference was
detected, further v2 tests were used to determine exactly
where the significant difference lay, with a Bonferroni cor-
rection being applied for multiple testing.
Sensitivity, specificity, and positive and negative pre-
dictive values (PPVs, NPVs) were calculated to assess
the performance of the SLICC-2012 and ACR/EULAR-
2019 classification criteria against the ACR-1997 criteria
(reference criteria). In these analyses, the UK JSLE
Cohort group of patients (n¼482) were combined with
the unselected ANA-positive patients (n¼ 129), with the
latter acting as a control group (total n¼ 611). Chi-
squared tests were used to calculate P-values for the
sensitivities and specificities, and the binomial exact
test was used to calculate P-values for the PPVs and
NPVs. McNemar’s test was used to assess for a differ-
ence between the ACR-1997 and ACR/EULAR2019 cri-
teria, the ACR-1997 and SLICC-2012 criteria, and the
SLICC-2012 and ACR/EULAR-2019 criteria, in the num-
ber of patients classified as having JSLE at first and
last visits.
In the absence of a definitive gold standard, the level
of agreement between the different criteria was also
assessed using receiver operator curves (ROCs). In
these analyses, the area under the curve (AUC) was cal-
culated for the following comparisons: ACR-1997 vs
ACR/EULAR-2019, ACR-1997 vs SLICC-2012, and
SLICC-2012 vs ACR/EULAR-2019 criteria. AUC values
of 1.0–0.9, 0.9–0.8, 0.8–0.7, 0.7–0.6 and 0.6–0.5 were
considered to be excellent, good, fair, poor and fail, re-
spectively [13]. Kappa coefficients were calculated to
assess inter-rater agreement between the criteria. A
kappa coefficient value of >0.4 was considered accept-
able [15, 16]. Absolute values and CIs for the AUC and
kappa coefficient are reported. All statistics were calcu-
lated using STATA 14 (StataCorp LLC, USA) and Excel
(Microsoft, USA). Results were considered significant if
the P-value was <0.05.
Results
UK JSLE Cohort Study participants’ clinical and
demographic features
From inception to date, the UK JSLE Cohort Study has
recruited 760 patients. A total of 482 patients met this
study’s inclusion criteria. The median age at diagnosis
was 12.8 years [interquartile range (IQR) 10.4–17.9], with
a male-to-female ratio of 1:5. Data on age of onset were
missing for 5 patients; therefore, of the 477 JSLE
patients where age of onset was available, 50 (10%)
were classified as having JSLE with disease onset at
<8 years of age (pre-pubertal), 268 (56%) at 8–13 years
(peri-pubertal), and 159 (33%) at 14–18 years of age
(adolescent). Median follow-up was 39 months (IQR 18–
195). Ethnicity data were missing for 10 patients. Of the
472 where ethnicity was known, 242 (50%) of patients
were White Caucasian, 140 (29%) were South Asian, 73
(15%) were Black African/Caribbean and 17 (4%) were
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of a mixed ethnic background. ANA positivity at first visit
was highest in patients presenting between 14–18 years
(95%) compared with other age groups (<8 years: 88%;
8–13 years: 93%). The demographic and clinical informa-
tion is summarized in Table 1.
Participants fulfilling SLE classification criteria at first
and last visits
The number of UK JSLE Cohort Study participants fulfill-
ing the ACR-1997, SLICC-2012 and ACR/EULAR-2019
classification criteria at the time of their first and last vis-
its are displayed in Fig. 1. At first visit, 385/482 (80%)
patients fulfilled the ACR-1997 criteria for SLE, 402/482
(83%) fulfilled the ACR/EULAR-2019 criteria and 443/
482 (92%) fulfilled the SLICC-2012 criteria. By the last
visit, 427/482 (89%) patients fulfilled the ACR-1997 crite-
ria, 434/482 (90%) fulfilled the ACR/EULAR-2019 criteria
and 463/482 (96%) fulfilled the SLICC-2012 criteria.
There was a significant increase in the number of
patients classified as SLE between the first and last vis-
its by all classification criteria (all P< 0.001). At both first
and last visits, the number of patients fulfilling the differ-
ent classification criteria (ACR-1997, SLICC-2012 and
ACR/EULAR-2019) varied significantly (P < 0.001 at
both first and last visits).
At the first visit, 30 (6%) patients who would other-
wise have scored 10 using the ACR/EULAR-2019 cri-
teria for SLE were ANA negative and therefore did not
fulfil the ACR/EULAR-2019 entry criterion for SLE [des-
pite 18/30 (60%) fulfilling either ACR-1997 or SLICC-
2012 criteria]. Of these patients, 15/30 (50%) subse-
quently developed ANA positivity, and therefore met the
ACR/EULAR-2019 criteria by their last visit. Further in-
formation on the individual criteria fulfilled by patients
who met the classification criteria threshold for one set
of criteria, but not the others, at their first visit is shown
in Supplementary Table S1, available at Rheumatology
online.
Clinical and laboratory criteria fulfilled
Individual clinical and immunological items fulfilled from
the three different classification criteria at first and last
presentations are displayed in Supplementary Table S2,
available at Rheumatology online. Of note, across the
UK JSLE Cohort Study, the proportion of ANA-positive
individuals increased from the first visit (448/482, 93%)
TABLE 1 Demographic details of the full UK JSLE Cohort Study, and those scoring 4 ACR-1997 criteria
Demographics Full UK JSLE Cohort Studya
n 5 482 (%)
ACR-19974
First visit, n 5 385 (%)b Last visit, n 5 427 (%)c
Ethnicity
White Caucasian 242 (51%) 180 (47%) 209 (49%)
Black African/Caribbean 73 (15%) 58 (15%) 66 (15%)
South Asian 140 (29%) 119 (31%) 128 (30%)
Other 17 (4%) 14 (4%) 15 (4%)
Gendera
Female 402 (83%) 318 (83%) 357 (93%)
Male 74 (15%) 61 (16%) 64 (17%)
Age
Median age at diagnosis (IQR) 12.8 (10.4–17.9) 12.9 (10.7–17.9) 12.8 (10.5–18.0)
Numbers of patients in different age groups
<8 years 50 (10%) 37 (10%) 43 (10%)
8–13 years 268 (56%) 218 (57%) 242 (57%)
14–18 years 159 (33%) 127 (33%) 138 (32%)
ANA positivity according to age group
<8 years 44 (88%) 34 (92%) 42 (98%)
8–14 years 249 (93%) 205 (94%) 233 (96%)
14–18 years 151 (95%) 125 (98%) 135 (98%)
Full UK JSLE Study Cohort includes patients fulfilling 4 ACR-1997 criteria and those fulfilling 2–3 ACR-1997 criteria.
Numbers of patients and percentages shown. aData missing for the full JSLE Study Cohort patients is as follows: (a) 5
patients for age, (b) 10 patients for ethnicity, (c) 38 patients for ANA, (d) 6 patients for gender. bData missing for the ACR-
19974 cohort patients at first visit is as follows: (a) 3 patients for age, (b) 14 patients for ethnicity, (c) 21 patients for
ANA and (d) 6 patients for gender in the subgroup of patients ACR-19974. cData missing for the ACR-19974 cohort
patients at last visit is as follows: (a) 4 patients for age, (b) 9 patients for ethnicity, (c) 17 patients for ANA and (d) 5
patients for gender in the subgroup of patients ACR-19974. P-values for comparisons made between each demographic
category within the full cohort (n¼482) are <0.001 for ethnicity, <0.001 for gender, <0.001 for age groups at diagnosis,
and 0.24 for ANA positivity according to age. P-values for differences between the first and last groups were not calcu-
lated, because the patients form the same overall group and are therefore not independent. Statistical analyses comparing
the demographic details between the full JSLE Study Cohort vs those fulfilling 4 ACR-1997 criteria at the first and last
visit are not undertaken, because there is overlap in the patients included in the different subgroups. ACR-1997: ACR
1997 revised version of criteria. IQR: interquartile range.








atology/article/60/11/5271/6159332 by guest on 17 N
ovem
ber 2021
to the last visit (463/482, 96%; P < 0.001), increasing
the number of individuals fulfilling the ACR/EULAR-2019
entry criterion. At the first visit, 10 patients exhibited
grade III or IV nephritis on biopsy, while testing negative
for ANA at inclusion/first visit. Three patients continued
to be ANA negative at the time of their last visit. A nega-
tive ANA would exclude these 10 patients at their first
visit and 3 patients at their last visit from classification
of SLE using the ACR/EULAR-2019 criteria.
SLE classification criteria in relation to age at
diagnosis within the full UK JSLE Study Cohort
(n 5 482)
Age-specific differences in clinical presentation and la-
boratory findings have previously been demonstrated in
CYP with JSLE [17]. To address the question of whether
the number of classification variables differed according
to age, JSLE patients were subdivided into the following
groups: pre-pubertal (<8 years), peri-pubertal (8–
13 years) and adolescent/post-pubertal (14–18 years)
(Table 2). For the ACR/EULAR-2019 criteria, a significant
difference was seen in the proportion of patients fulfilling
the criteria according to age, at both first (P ¼ 0.02) and
last visits (P ¼ 0.001). At first visit, a lower proportion of
pre-pubertal patients (32/50, 64%) fulfilled the ACR/
EULAR-2019 criteria as compared with both peri-
pubertal (8–13 years; 219/268, 81%, P ¼ 0.04) and ado-
lescent patients (14–18 years; 126/159, 79%; P ¼ 0.002,
Table 2). This likely relates to the observation that ANA
positivity was numerically highest at diagnosis in adoles-
cent patients (14–18 years: 151/159, 95%) when com-
pared with other age groups (<8 years: 44/50, 88%; 8–
13 years: 249/268, 93%) (Table 1). This difference was
not seen using either the ACR-1997 or SLICC-2012 cri-
teria (P-values > 0.05).
Performance of the SLE classification criteria in an
unselected paediatric population testing positive for
ANA and the full UK JSLE Study Cohort combined
To test the sensitivity, specificity, PPVs and NPVs of
the classification criteria in ANA-positive CYP inde-
pendent of their final diagnosis, the ACR-1997 criteria
were used as the reference criteria in an unselected
population of CYP who tested positive for ANA at Alder
FIG. 1 Patients classified as having JSLE at first and last visit using three sets of criteria
Full UK JSLE Cohort Study: 482 patients. Section sign indicates Chi squared test used to calculate P-values for dif-
ferences in the numbers classified using each set of criteria. P-value at first (P ¼ 0.007) and last visit (P < 0.001).
Hash symbol indicates McNemar’s test was used to calculate the P-values for differences in the number classified
initially and finally by individual classification criteria: ACR-1997, P < 0.001, ACR/EULAR-2019, P ¼ 0.0003; SLICC,
P ¼ 0.0001.
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Hey Children’s Hospital over a 12 month period
(n¼129), combined with 482 CYP from the UK JSLE
Cohort Study (n¼ 611 total). The unselected ANA-
positive CYP cohort consisted of 92 females and 37
males, with a median age of 11 years (IQR 7–17)
(Supplementary Table S3, available at Rheumatology
online).
At both the first and last visits, sensitivity of the
SLICC-2012 criteria (both 98%) was comparable with
that of the ACR-1997 criteria, and higher when com-
pared with the ACR/EULAR-2019 criteria (first visit:
94%, last visit: 96%, both P < 0.001). Conversely,
specificity of the SLICC-2012 criteria was significantly
lower compared with that of the ACR/EULAR-2019 cri-
teria at both first (SLICC-2012: 67% vs ACR/EULAR-
2019: 77%, P < 0.001) and last visits (SLICC-2012:
71% vs ACR/EULAR-2019: 81%, P < 0.001).
The proportion of CYP fulfilling the classification cri-
teria who were correctly identified as JSLE (PPV, based
on the ACR-1997 reference criteria) was higher using
the ACR/EULAR-2019 criteria compared with when
using the SLICC-2012 criteria at both first and last vis-
its (88% at first and 93% at last visit for the ACR/
EULAR-2019 criteria, vs 84% at first and 89% at last
visit for the SLICC-2012 criteria, Table 3). Conversely,
the proportion of CYP not fulfilling the criteria and cor-
rectly identified as not having JSLE (NPV) was lower
for the ACR/EULAR-2019 criteria compared with the
SLICC-2012 criteria (87% at first and 89% at last visit
for ACR/EULAR-2019, vs 95% at both first and last
visit for SLICC-2012).
Level of agreement between classification criteria
In the absence of a gold standard test for JSLE, ROC
curves and kappa coefficient analysis were used to as-
sess levels of agreement between the ACR/EULAR-2019
criteria and the previous criteria (Table 4). When the
ACR-1997 criteria were used as the reference criteria to
classify patients as having JSLE, the AUC for the ACR/
EULAR-2019 criteria was 0.78 (CI: 0.73, 0.83). The
kappa coefficient for inter-rater agreement between the
ACR-1997 and the ACR/EULAR-2019 criteria was 0.58
(CI: 0.53, 0.63). When the SLICC-2012 criteria were
used as the reference criteria to classify CYP as having
JSLE, the AUC for the ACR/EULAR-2019 criteria was
0.89 (CI: 0.75, 0.90), and the kappa coefficient for inter-
rater agreement between the two criteria was 0.76 (CI:
0.69, 0.78). This demonstrated variable agreement be-
tween the different criteria, with the strongest agreement
being between the ACR/EULAR-2019 and SLICC-2012
criteria.
False-positive classification of CYP using the ACR/
EULAR-2019 in an unselected CYP cohort testing
positive for ANA
A total of 6/129 (5%) individuals in the aforementioned
cohort tested positive for ANA, despite having an
TABLE 2 Number of UK JSLE Cohort patients fulfilling the different classification criteria for SLE (by age)
Number of patients fulfilling the
ACR-1997 criteriaa
Number of patients fulfill-
ing the ACR/EULAR-2019
criteriaa
























































P-value 0.5 0.4 0.02* 0.001** 0.2 0.7
Numbers displayed are those patients fulfilling the different classification criteria, with percentages in brackets. Overall, pa-
tient age was not available for 5/482 UK JSLE Cohort Study patients. aOf the patients fulfilling 4 ACR-1997 revised crite-
ria for classification of SLE (n¼385 at first visit and n¼427 at last visit), age was unknown in 3 patients at the first visit
and 4 patients at the last visit. Of patients scoring 10 using the ACR/EULAR-2019 criteria (n¼402 at first visit and
n¼434 at last visit), age was unknown in 4 patients at the first visit and 4 patients at the last visit. Of the patients fulfilling
4 SLICC-2012 criteria (n¼441 at the first visit and n¼463 at the last visit), age was unknown in 4 patients at the first
visit and 4 patients at the last visit. ACR-1997: ACR 1997 revised version. v2d tests used to calculate P-values when com-
paring the proportion of patients fulfilling different criteria, for individual age groups at an individual visit (either first or last
visit). From post hoc analysis, one asterisk indicates a significant difference between the pre-pubertal and peri-pubertal
age groups (P ¼ 0.04), and the pre-pubertal and adolescent age groups (P ¼ 0.002), and two asterisks indicate a signifi-
cant difference between the pre-pubertal and peri-pubertal age groups (P ¼ 0.05) and the pre-pubertal and adolescent
age groups (P ¼ 0.05).
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alternative diagnosis (false positives). Of these, 5/6 met
the ACR/EULAR-2019 criteria, 4/6 met the SLICC-2012
criteria, and 2/6 met the ACR-1997 criteria for SLE
(Table 5). Two patients fulfilled all three SLE classifica-
tion criteria, including one patient with RNP-positive
mixed connective tissue disease and one patient with
biopsy-proven renal dysplasia. Two patients exclusively
fulfilled the ACR/EULAR-2019 criteria, including one pa-
tient diagnosed with Cornelia de Lange syndrome and
one with IgA vasculitis. One patient diagnosed with JDH
met both the ACR/EULAR-2019 and the SLICC-2012 cri-
teria, and one patient with LPS-responsive beige-like an-
chor protein (LRBA) gene mutation with idiopathic
thrombocytopenic purpura and hypogammaglobulinae-
mia met the SLICC-2012 classification criteria.
Discussion
Classification criteria are important and accepted tools
allowing selection of homogeneous patient cohorts for clin-
ical trials. By definition, classification criteria therefore aim
for high specificity while allowing reduced sensitivity [3, 4,
18, 19]. This discriminates classification from diagnostic cri-
teria, which aim for high sensitivity while accepting reduced
specificity to not miss patients in the diagnostic process
[18]. Recently published ACR/EULAR-2019 criteria for SLE
were the result of a consensus process of adult rheumatol-
ogists, aiming at a homogeneous case definition of SLE
patients, not primarily considering potential differences be-
tween JSLE and adult-onset disease. Paediatric rheumatol-
ogists were not involved in the process, and JSLE cohorts
were also not included in performance testing. Therefore to
date, it remains largely unclear whether these new criteria
perform sufficiently well in CYP with JSLE [9, 20].
Two recent studies have assessed the performance of
ACR/EULAR-2019 criteria in JSLE [10, 11]. The first
study included 122 JSLE patients and 89 controls (ANA
positive with other rheumatic diseases). Using an ACR/
EULAR-2019 criteria cut-off score of 10, the new crite-
ria were less specific at the time of the first visit (67.4%)
than both the ACR-1997 (83.2%) and the SLICC criteria
(80.9%). For sensitivity, the new ACR/EULAR-2019 crite-
ria scored better than ACR 1997 (87.7% vs 70.5%) and
worse than the SLICC-2012 criteria (89.3%). The authors
assessed additional cut-off points for the new ACR/
EULAR-2019 score, showing a score of 13 resulting in
increased specificity, and improved PPV and cut-off
point accuracy [11].
The second study included 112 SLE patients aged 2–
21 years (with JSLE and adult-onset SLE) and 105 con-
trols aged 1–19 years (with other rheumatic diseases).
TABLE 3 Sensitivity, specificity, and positive and negative predictive values of ACR/EULAR-2019 and SLICC-2012
criteria

















ACR/EULAR-2019 94 96 77 81 88 93 87 89

















The ACR-1997 criteria were used as reference criteria for calculation of sensitivities, specificities, and positive and negative
predictive values. *P-values were calculated using the v2d test, comparing the sensitivities or specificities obtained by the
different classification criteria (ACR/EULAR-2019 vs SLICC-2012) at each time point. **P-values calculated using a binomial
exact test, and relating to positive predictive value and negative predictive value for each set of criteria.
TABLE 4 Level of agreement between classification criteria
Reference criteria Comparator criteria AUC
(CI)
Kappa coefficient (CI)
ACR-1997 ACR/EULAR-2019 0.78 (0.73, 0.83) 0.58 (0.53, 0.63)
SLICC-2012 0.63 (0.54, 0.67) 0.37 (0.27, 0.41)
SLICC-2012 ACR/EULAR-2019 0.89 (0.75, 0.90) 0.76 (0.69, 0.78)
ACR-1997: ACR 1997 revised version, AUC from ROC curves generated using data from the full UK JSLE Cohort Study,
n¼482. AUC: area under the curve.
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The rheumatologist’s diagnosis of SLE served as the ref-
erence standard criterion. The authors showed the ACR/
EULAR-2019 criteria to have higher sensitivity (85% vs
72%; P ¼ 0.023) and similar specificity (83% vs 87%; P
¼ 0.456) when compared with the 1997-ACR criteria.
On examining the ACR/EULAR-2019 classification sum-
mary scores according to ethnicity, the absolute scores
were higher in non-White than White patients (22þ10 vs
17þ 9; P < 0.01). Sub-analysis showed sensitivity of the
criteria was not influenced by patient ethnicity, age or
gender [10].
In this present study including a markedly larger na-
tional study population (the UK JSLE Cohort Study), dif-
ferences between the ACR-1997 and SLICC-2019 vs the
ACR/EULAR-2019 criteria were mainly caused by the
absence of the entry criterion, ANA positivity, affecting a
total of 30 CYP (6%). Indeed, higher frequencies of
ANA-negative patients diagnosed and/or classified as
having JSLE have been reported previously, and are
therefore a concern in relation to the ACR/EULAR-2019
criteria [17]. ANA negativity, especially in young JSLE
patients, may be associated with a strong genetic con-
tribution to disease pathology (e.g. monogenic causes
or an increased number of risk alleles), which may cause
systemic inflammation and tissue damage (initially) in
the absence of autoantibodies. Indeed, a higher relative
prevalence of genetic forms of SLE (recently estimated
to be 7% [21]) and a higher number of risk alleles with-
in individuals across the remaining JSLE patient popula-
tion [22] likely contribute to more severe clinical
phenotypes with increased disease activity and organ
damage, and higher proportions of ANA-negative
patients when compared with adult-onset SLE [23]. Of
note, over time, 50% of initially ANA-negative JSLE
patients in the UK JSLE Cohort Study developed ANA
positivity, and therefore at their last visit also met the
ACR/EULAR-2019 criteria. While one could argue that
this is of benefit when selecting homogeneous popula-
tions for clinical trials, it creates problems for JSLE
patients in whom their condition is evolving and who de-
velop autoantibody positivity over time [17].
Another concern is that in the in absence of widely
agreed diagnostic criteria for SLE, many healthcare pro-
fessionals use classification criteria to aid diagnosis.
Using the ACR/EULAR-2019 criteria to do this would re-
sult in a significant proportion of JSLE patients (espe-
cially ANA-negative patients) that may be missed.
Unfortunately, this will mostly affect young JSLE
TABLE 5 False-positive classification of SLE in unselected ANA-positive control cohort
Individual patients and diag-
nosis at the time of analysis
Clinical features Classification criteria scores
ACR/EULAR-2019
score (n 5 5)
SLICC-2012
score (n 5 4)
ACR-1997
score (n 5 2)











3 Cornelia de Lange syndrome
with OA
ANA positivity, OA and low
complement
10 N/A N/A
4 IgA vasculitis ANA positivity, arthritis and
proteinuria
10 N/A N/A
5 JDM ANA positivity, malar rash,
arthritis and low C4
10 4 N/A







ACR-1997: ACR 1997 revised version, classified as SLE if score 4 points. ACR/EULAR-2019, classified as SLE if score
10 points. SLICC-2012, classified as SLE if score 4 points. aRenal dysplasia was demonstrated on biopsy, with no in-
flammation demonstrated and negative immunofluorescence. The electronic records of these patients were rechecked 18–
24 months after the initial positive ANA measurement, confirming that none of the initial diagnoses had changed over this
time period. DAT: direct antiglobulin test; MCTD: mixed connective tissue disease; RNP þve : RNP antibody positive;
LRBA: LPS-responsive beige-like anchor protein; ITP: idiopathic thrombocytopenia purpura; N/A: non-applicable (criteria
threshold not met).
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patients, in whom diagnosis can already be delayed
[24]. Particularly among pre-pubertal JSLE patients (pre-
pubertal, <8 years), fewer individuals fulfilled the ACR/
EULAR-2019 criteria when compared with the ACR-
1997 and SLICC-2012 criteria [17].
Using a combined cohort including the UK JSLE
Cohort Study participants and the unselected ANA-
positive CYP to calculate specificity, sensitivity and pre-
dictive values, based on the ACR-1997 criteria as refer-
ence criteria, reduced sensitivity was calculated for the
ACR/EULAR-2019 criteria compared with the SLICC-
2012 criteria, while specificity was higher in the ACR/
EULAR-2019 criteria compared with the SLICC-2012 cri-
teria. This confirms findings from above in a larger co-
hort including additional differential diagnoses, and
indicates that inclusion of ANA as an entry criterion may
reduce sensitivity, while potentially increasing specificity.
Thus, if (incorrectly) used to diagnose patients, the ACR/
EULAR-2019 criteria may miss individuals and/or delay
diagnosis in CYP who develop autoantibodies later in
disease, including those cases resulting from monogenic
disease causes [17].
As classification criteria aim at high specificity while po-
tentially accepting slightly reduced sensitivity, we investi-
gated an unselected cohort of ANA-positive CYP. Five
patients were falsely classified as having JSLE using the
ACR/EULAR-2019 criteria, while this was the case in four
patients when using the SLICC-2012 criteria and in two
individuals when using the ACR-1987 criteria. Thus, speci-
ficity of the EULAR/ACR-2019 criteria may indeed be lim-
ited when compared with that of other sets of criteria,
resulting in false-positive results. Other immune complex–
mediated conditions with ANA positivity and renal involve-
ment are of particular concern (e.g. IgA vasculitis) [25].
Taken together, while it is challenging to propose
changes to consensus-based classification criteria
developed following a stringent process, including ac-
cess to patient data and clinical findings across large
(adult) SLE cohorts, from a paediatric perspective, main
concerns in relation to false-positive or -negative classi-
fication include (i) ANA antibody positivity as an entry
criterion (missing a significant proportion of young JSLE
patients (17]), and (ii) the combination of ANA positivity
and immune complex vasculitis triggering classification
as SLE (as this may be present in IgA vasculitis, a rela-
tively common condition in childhood).Thus, additional
studies further investigating the performance of the
ACR/EULAR-2019 classification criteria in multi-ethnic
cohorts, across ages, and at different disease stages
are warranted. Inclusion of subcohorts of CYP with dif-
ferent systemic inflammatory diseases will be critical for
reliably evaluating specificity and sensitivity.
The absence of widely accepted diagnostic tools for
JSLE meant that the ACR-1997 criteria needed to be
used as a reference standard. Particular strengths of this
cohort are the availability of longitudinal data in a national
cohort, allowing assessment of classification criteria
performance at different disease stages (first vs last
visits). This, and the significantly larger sample size are
key enhancements when compared with the two previ-
ous studies comparing the ACR/EULAR-2019 criteria
with the ACR-1997 and SLICC-2012 criteria in JSLE
cohorts. Future assessment of how these criteria perform
in an international cohort of JSLE patients is also
warranted.
Conclusions
Based on observations in a large national JSLE cohort
(the UK JSLE Cohort Study), the ACR/EULAR-2019 cri-
teria miss a significant proportion of pre-pubertal JSLE
patients, mostly because of the absence of ANA positiv-
ity. Performance improves with age, and sensitivity (ini-
tially reduced) is comparable with that of the SLICC-
2012 criteria at the last visit. Overall, the specificity is
higher when compared with the SLICC-2012 criteria.
However, concerns remain due to more false positives
being seen using the ACR/EULAR-2019 criteria. Given
the rarity of JSLE, some clinicians will have limited ex-
perience in making the diagnosis of JSLE and may rely
on classification criteria to aid diagnosis. Doing this with
the ACR/EULAR-2019 criteria, a significant proportion of
JSLE patients (especially ANA-negative patients) may be
initially missed, leading to diagnostic delay, morbidity
and potentially mortality. If classification criteria are
designed to include paediatric and adult populations,
paediatric specialists should be consulted and included
in the consensus and evaluation process, as seemingly
minor differences can affect outcomes.
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